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Prediction of 5-fluorouracil cytotoxicity towards the Walker
carcinosarcoma using peak integrals of fluoronucleotides measured by
MRS in vivo
P.M.J. McSheehy, M.J.W. Prior & J.R. Griffiths
CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry, Jenner Wing, St George's Hospital
Medical School, Cranmer Terrace, London SWJ7 ORE, UK.
Summary '9F-magnetic resonance spectroscopy (MRS) can be used to non-invasively monitor metabolism of
5-fluorouracil (5FU) to cytotoxic fluoronucleotides (FNuct). We investigated whether the levels of FNuct
formed from 5FU and observed in vivo by MRS in the Walker carcinosarcoma predicted cytotoxicity. Fifty
mgkg-1 5FU caused tumour FNuct formation and, when repeated daily for 1 week, significant tumour
growth inhibition (P<5%). Twenty-five mgkg-1 5FU produced less tumour FNuct (P<5%) and did not
cause significant tumour regression. Tumour regression and tumour FNuct formation were also suppressed by
50mgkg-1 5FU combined with a molar equivalent dose of allopurinol (P<2%). Tumour extracts were
analysed by hplc and MRS confirming the observations in vivo and demonstrating that peak integrals in vivo
were directly proportional to 5FU and FNuct concentrations. Hplc analysis of extracts showed that 50% of
FNuct in tumours treated with 5FU was the cytotoxic nucleotide FUTP; this was lowered to 5% by a molar
equivalent dose of allopurinol (P<2%). Twenty-five mgkg-1 5FU also produced significantly less FUTP
(36%) than the 50mgkg-' dose (P<5%). These results suggest that MRS-detectable changes in tumour
FNuct (mostly in FUTP) can be used to predict 5FU cytotoxicity.
The xenobiotic 5-fluorouracil (5FU), which has been in
clinical use for the past 30 years, is now used predominantly
against gastrointestinal and breast cancer (Heidelberger et
al., 1983). Clinical success is low against human tumours,
even in combination with other drugs such as methotrexate
or allopurinol, while host toxicity remains a problem
(Mackintosh & Tattersall, 1987). However, until more
effective drugs are found it is necessary to improve the
efficacy of those drugs currently available.
Chemotherapy could be optimised more easily if early
indicators of tumour responsiveness were available. 19F-
NMR spectroscopy (MRS) is a non-invasive technique that
can be used to follow the transformations of a drug as they
occur in situ (Stevens et al., 1984). The metabolism of 5FU is
summarised in Figure 1. Detoxification (catabolism) occurs
predominantly in the liver, while cytotoxicity is most likely
mediated by the formation of two fluoronucleotides: 5-
fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP). FdUTP can be
incorporated into DNA but is thought to be removed by
uracil-DNA glycosylase and thus this deoxynucleotide may
not be important in 5FU cytotoxicity (Pinedo & Peters,
1988) (Figure 1). FdUMP inhibits thymidylate synthase
which in the absence of thymidine blocks DNA synthesis,
while the ribonucleotide interferes with RNA metabolism
(Heidelberger et al., 1983). FUTP and FdUMP have
different chemical shifts in vitro (0.1-0.2 p.p.m. resolution)
(Keniry et al., 1986; Cabanac et al., 1988), but these and the
other fluoronucleotides are indistinguishable by MRS in vivo,
having similar pH-dependent chemical shifts of 4.5-5 p.p.m.
downfield from 5FU. We will therefore refer to the
combined peak as fluoronucleotide (FNuct). This FNuct
signal, which would also include signals from any FUDP-
sugars can be resolved by MRS in vivo from the two 5-
fluoronucleotides (FUrd and FdUrd) which have a chemical
shift of 3.5-3.8 p.p.m. downfield from 5FU (Keniry et al.,
1986; Malet-Martino et al., 1986).
FNuct has been observed in mouse liver in vivo by MRS
(Hull et al., 1987; Prior et al., 1987; Cabanac et al., 1988).
More intense signals were detected in mouse tumours
(Stevens et al., 1984; Hull et al., 1986; Koutcher et al., 1987)
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and in a rat pituitary tumour, the SG prolactinoma
(Griffiths et al., 1987). Apparent increases in the amount of
FNuct generated in vivo can be induced by appropriate
combination chemotherapy, but this was not related to
increased cell death or tumour regression (Stevens et al.,
1984; Hull et al., 1987; Koutcher et al., 1987). Such work is
gradually being extended to patients where signals
corresponding to 5FU and the catabolite ax-fluoro-p-alanine
(FBal) (19 p.p.m. upfield from 5FU) have been detected in
liver (Wolf et al., 1987). It was reported recently that FNuct
has been observed in liver metastases after treatment with
5FU (Semmler et al., 1988). However, these experiments did
not demonstrate whether the presence of the FNuct peak
was related to cytotoxicity.
We have studied 5FU metabolism in the Walker
carcinosarcoma grown s.c. in rats which rapidly metabolises
5FU to FNuct (Klubes et al., 1978). Our objective was to
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Figure 1 The pathways of 5FU metabolism. Abbreviations are
as follows: allopurinol (HPP), 5-fluorouracil (5FU), 5,6-dihydro-
fluorouracil (FUH2), a-fluoroureidopropionic acid (FUPA), a-
fluoro beta-alanine (FBL), 5-fluorouridine (FURD), and its 5'-
monophosphate (FUMP), diphosphate (FUDP), and
triphosphate (FUTP), 5-fluoro-2'-deoxyuridine (FdURD), and its
5'-monophosphate (FdUMP), diphosphate (FdUDP), and
triphosphate (FdUTP), 5FU incorporated into DNA (FU-DNA),
5FU incorporated into RNA (FU-RNA). Enzymes are numbered
as follows: (1) dihydrouracil dehydrogenase; (2) thymidine
phosphorylase; (3) uridine phosphorylase; (4) thymidine kinase;
(5) uridine kinase; (6) pyrimidine phosphoribosyl transferase; (7)
uracil DNA-glycosylase. The metabolism of HPP causes an
inhibition of the conversion of 5FU to FUMP by indirectly
reducing the available levels of PPRT and the co-substrate
pyrimidine phosphoribosyl pyrophosphate.
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determine whether MRS-visible levels of this species pre-
dicted cytotoxicity. We aimed to alter tumour levels of
FNuct in vivo in two ways by: (a) varying the 5FU dose
from 25mgkg-1 (low) up to 50mgkg-1 and 120mgkg-1
(high); (b) modulating 5FU metabolism by combination
chemotherapy using allopurinol (HPP). HPP is activated to
oxypurinol monophosphate which inhibits the enzyme oroti-
dylate decarboxylase responsible for the conversion of oroti-
dine monophosphate to uridine monophosphate. The inhibi-
tion raises intracellular levels of orotate which has a higher
affinity for the enzyme pyrimidine phosphoribosyl trans-
ferase (PPRT) responsible for the conversion of 5FU to
5-fluorouridine monophosphate (FUMP) (Schwartz &
Handschumacher, 1979) (Figure 1). The activation of HPP
also uses the co-substrate phosphoribosylpyrophosphate
which is used to convert 5FU to FUMP and thus HPP
indirectly inhibits the PPRT pathway by two mechanisms
which should lead to an overall reduction in FNuct (Howell
et al., 1981). Indeed using MRS in vivo, we have shown that
HPP causes a significant decrease in FNuct formation from
5FU in isolated Walker 256 and Ehrlich ascites tumour cells
(Prior et al., 1987).
Materials and methods
Drugs and chemicals
5FU as the sodium salt in water was obtained from David
Bull Laboratories (Warwick, UK). 5-Fluorotryptophan,
FdUMP and HPP were purchased from Sigma Chemical Co.
(Poole, Dorset, UK). HPP (4-hydroxypyrazolo pyrimidine)
(or allopurinol) was dissolved in 0.9% NaCl containing 0.2M
NaOH. 5-Fluorouridine monophosphate (FUMP) was
purchased from Calbiochem (Cambridge, UK).
Tumour management
In all studies the rats used were female Wistars of weight
180-200g. The Walker 256 carcinosarcoma cells (passage
number 550-553) were stored at 108 cellsml-l in Hams FlO
medium containing 20mM HEPES and 5% fetal calf serum
(FCS) (Flow Laboratories) with 10% dimethyl sulphoxide at
- 196°C. Cells were thawed, washed twice in 0.9% saline
and injected i.p. (5 x 106) into the rats. After 4-5 days the
cells were harvested, washed and viability was determined
using the trypan blue (0.1%) exclusion test. The cells were
suspended in FIO medium containing 5% FCS and were
injected s.c. (2 x 107) into one flank; one injection was given
to each rat. Tumours were normally grown for 6-10 days
and were used for MRS studies when greater than 400mm2,
i.e. a diameter greater than that of the surface coil used.
Assuming the tumours were prolate spheroids with a density
of 1.0, this area would correspond to a weight of 4g (Klubes
et al., 1978). Walker carcinosarcomas of this size and up to
weights of about 15g show little or no necrosis (Stubbs et
al., 1988).
For studies of inhibition of tumour growth the rats (9 or
10 in each group) were injected s.c. with Walker cells on day
0. On the next and each subsequent day up to and including
day 7, rats received 0.9% saline i.p., 50mgkg- 1 or
25mgkg 1 5FU i.p. or the combination of 5FU and a molar
equivalent dose of HPP (52 or 26mgkg-1) i.p. Rats were
weighed each day to assess toxicity. On day 8 the rats were
killed and the tumours were excised and weighed.
19F-NMR spectroscopy
All spectra were obtained at 75.5MHz and 20-22°C using a
1.9T 30cm horizontal bore magnet (Oxford Research
Systems). Spectra (480 transients, spectral width of 3-4kHz)
were obtained in vivo using a 1.5cm diameter 2-turn surface
coil, with 14Ms radiofrequency pulses and a 1s repetition
time. With this coil a 900 flip angle at the coil centre
corresponded to a 7ps pulse. The receiver gains and all other
acquisition parameters were identical for each tumour
studied. Rats were anaesthetised with an i.p. injection of
sodium pentobarbitone before the jugular vein was
cannulated. The surface coil was positioned so that it was on
the middle of the tumour and touching the surface. In this
position we obtained shims from the proton peak of
32+9Hz for controls and 35+10Hz for tests (mean+s.d.,
n=8). Rats without any previous treatment received 25, 50
or 120mgkg-1 5FU as an i.v. bolus injection (controls), or
in addition a molar equivalent i.v. bolus of HPP, 15min
before the SFU. Simultaneous with the administration of
SFU, individual spectra were acquired for consecutive 8min
intervals until 67min at which time the tumours were rapidly
excised and freeze-clamped. The spectra shown in the figures
are the sums of four consecutive 8 min spectra for the
labelled time periods. The time points for the kinetic time
course plots indicate the midpoint of each total time period.
This technique is equivalent to a 4-point smoothing
procedure for 8min data, but it was necessary in order to
achieve reasonable signal-to-noise at doses below
120mgkg-1 5FU, and we also used this method to compare
the different 5FU doses. These spectra, obtained in vivo,
were given 19Hz line broadening and the integrals of the
peaks were measured using the Oxford Research Systems
analysis program to give an area (in arbitrary units) for each
peak. In Figure 8, where arbitrary units are plotted against
nmolg-1, the zero point on the ordinate does not necessarily
correspond to 0nmolg-1, but is the sensitivity limit of MRS
under our conditions. All chemical shifts are referenced
relative to SFU (0 p.p.m.).
Acid extracts
Tumour extracts were made (normally 3g from each tissue)
using 4ml of cold 6% (v/v) perchloric acid per gram of
tissue and were neutralised with KOH. The extracts were
freeze-dried and concentrated to a 3ml solution. Aliquots
(100 l) were stored at -200C for hplc and the remainder
was analysed by MRS. In vitro spectra (at least 1,500
transients with a spectral width of 6kHz) were obtained
using a solenoid coil, 9is pulses (flip angle=900) and an
8.5 s repetition time. For quantitative analysis a capillary
containing 300nmol of 5-fluorotryptophan solution was used
as an external standard. The same amount of standard was
used for every extract and was always placed in the same
position in the coil. An 8.5 s interval was found to be
sufficient to relax 5FU, FBal, FNuct and the external
standard under our conditions in vitro.
Hplc
Samples were analysed using a 100 mm x 5 mm Hypersil-
APSII weak anion-exchange column and a Jones
Chromatography Integrator (Hengoed, Glamorgan, UK). A
16min linear concentration gradient was generated from
potassium phosphate (3 g -1), pH2.8 (Aristar grade, BDH
chemicals, Poole, UK) and potassium phosphate (90 g -1),
pH 3.3 both prepared with doubly glass-distilled water and
Analar HCI. All samples added to the column contained
0.05mM cytidine diphosphate as an internal standard.
Measurements were made at both 254nm and 280nm to
quantify the fluorinated UMP, UDP and UTP according to
the method of M.J.W. Prior (personal communication).
FUMP, FdUMP, FUDP and FUTP were used as standards,
the latter two synthesised from FUMP by the method of
Pogolotti et al. (1981).
Statistics
Most analyses used an unpaired two-tailed Student's t test,
assuming equal variances. Where variances were significantly
different (F test, 2.5 percentage points) an approximate t test
was used. In Table I, where three groups were compared,
Gabriel's one-way analysis of variance was used (Kendall &
Stuart, 1968).19F-NMR OF 5-FLUOROURACIL METABOLISM IN TUMOURS
Table I The effect of 5FU (25mgkg 1 ore SOmgkg-1) and-5-FU+HPP on the
growth of the Walker carcinosarcoma
25mgkg 1 5FU 50mgkg1 SFU
% wt increase % wt increase
Treatment Tumour wt (g) of rat Tumour wt (g) of rat
None 6.8+1.5 11.8+0.2 6.4+2.2 12.5+ 3.0
5FU 5.6+1.0 4.7+1.0 1.2+0.5a 1.9+ 6.5
5FU+HPP 7.0+1.0 4.6+1.1 2.8+0.7 9.7+16.2
Measurements were made 8 days after innoculation of the rats with tumour cells.
Animals were treated daily for 7 days as described in Methods. Results are from two
separate studies and are the mean+s.e. of 10 rats per group (25mgkg-1 5FU) and 9
rats per group (50mgkg-1).
ap<0.05, when compared to no treatment using Gabriel's one-way analysis of
variance.
Results
The Walker carcinosarcoma grew in a reproducible manner
doubling in size approximately every 24h, and normally
reached a weight of about 6g after 8 days' growth (Table I).
This growth was not inhibited by a daily dose of 25mgkg-1
5FU and at this dose general toxicity was low. Two separate
studies (one shown) demonstrated that doubling the daily
5FU dose caused a significant reduction in tumour weight by
day 8, although this was associated with a large weight loss
for the rat (Table I). Coadministration of HPP prevented
toxicity, but the combination regime did not cause a
significant reduction in tumour weight. This result is similar
to observations made using murine leukaemia cell lines in
vitro, where HPP antagonised the growth inhibitory action
of 5FU (Schwartz & Handschumacher, 1979).
Following the i.v. bolus injection, low doses of 5FU
(which had no effect on the tumour growth) produced very
little FNuct signal; indeed FNuct was seen in only two out
of four injected with this dose. With a 50mgkg-1 dose
(which did cause significant retardation of tumour growth)
5FU was seen in all the tumours within 8min. The fluoro-
nucleotides (FNuct) gradually appeared while the 5FU peak
integral diminished until 33-67min, when the peak area ratio
of FNuct/5FU was about one. The pattern of metabolism
that we observed in the absence of HPP was consistent from
one tumour to another. Figure 2 includes a summary of
results from three tumours that received this dose. In acute
experiments with a dose of 120mgkgt (too toxic to be used
for studies on tumour growth) the pattern of 5FU
metabolism was similar (Figure 3). The apparent lag-phase
(0-17min) at this dose may not be real since zero arbitrary
units does not necessarily reflect Onmolg-1 but just the
sensitivity limits of the machine (see Materials and methods).
Figure 4 shows this typical pattern of metabolism in an
individual tumour that received the high dose of 5FU.
An injection of a molar equivalent dose of HPP, 15min
before 5FU, markedly altered the concentration of 5FU
metabolites. FNuct was not seen at all at 50mgkg-1 (Figure
5) and only small signals were seen in two of four tumours
at the 120mgkg- dose (Figure 6). The rate of 5FU
disappearance also appeared slower at 50mgkg-1 (Figure 2),
while at 120mgkg-1 the 5FU signal remained at the same
intensity throughout the experiments (Figure 3).
Signals corresponding to the catabolite FBal were seen
only occasionally in vivo and were apparently independent of
the 5FU dose or drug combination used. Signals
corresponding to the 5-fluoronucleosides (FNucs) were never
observed in these tumours in vivo. The chemical shift
between 5FU and FNuct showed some small intertumoral
variation, but on average suggested a pHi range of 6.9-7.3
using the titration curves of Keniry et al. (1986). In
summary, the above results showed that a higher tumour
formation of FNuct (increased FNuct peak integral) was
associated with increased 5FU cytotoxicity towards the
Walker carcinosarcoma.
Extracts from these tumours were analysed quantitatively
by both MRS and hplc. MRS in vitro confirmed
observations in vivo, namely the presence of 5FU and FNuct
and the absence of the FNucs metabolites in the tumours
(Figure 7). Spectra in vitro demonstrated that FBal was
nearly always present following 5FU administration, but
overall there was no correlation between FBal concentration
and the type of drug regime given to the rat. Table II
compares quantitation of the tumour extracts by MRS in
vitro with the mean peak areas measured in vivo. This table
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Figure 2 Peak integrals of 5FU and FNuct in the Walker
carcinosarcoma following an i.v. bolus injection of 5FU
(50mgkg-1) in the absence and presence of HPP. Rats receiving
a molar equivalent dose of HPP were injected i.v. 15min before
5FU. Results are the mean+s.e. of three tumours (control) and
four tumours (HPP). 0, 5FU in controls; 0, FNuct in controls;
A, 5FU in HPP-pretreated rats.
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Figure 3 Peak integrals of 5FU and FNuct in the Walker
carcinosarcoma following an i.v. bolus injection of 5FU
(120mgkg-1) in the absence and presence of HPP. Rats
receiving a molar equivalent dose of HPP were injected i.v.
15 min before 5FU. Results are the mean+s.e. of 5 tumours
(control) and 4 tumours (HPP). 0, 5FU in controls; 0, FNuct
in controls; A, 5FU in HPP-pretreated rats.
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Figure 4 Metabolism by Walker carcinosarcoma of 5FU
(120mgkg-1). Rats received an i.v. bolus injection of 5FU at
zero time. The receiver gains were already set to maximum and
data acquisition began immediately after 5FU injection. The
spectral width was 4kHz and a 1 s repetition time was used. Each
spectrum is the sum of four 8min blocks of 480 transients
processed with 19Hz line broadening. Peaks identified as follows:
FU, 5-fluorouracil; FN, 5-fluoronucleotides (deoxy and non-
deoxy) and FUDP-sugars.
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Figure 5 Metabolism by Walker carcinosarcoma of 5FU
(S0mgkg 1) in the presence of HPP. Rats received an i.v. bolus
injection of 5FU at zero time, 15min after a molar equivalent
i.v. bolus injection of HPP. The spectral parameters and the
processing of results were identical to that described in the
legend to Figure 4.
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Figure 7 Spectra of extracts from Walker carcinosarcomas
freeze-clamped 67min after a bolus injection of 5FU
(120mgkg-1). a, 5FU alone; b, 5FU 15min after a molar
equivalent dose of 5HPP. The spectral width was 6kHz. Each
spectrum was from 1,500 transients, with an 8.5 s repetition time
and was processed with 19Hz line broadening. Peaks identified
as follows: FT, 300nmol 5-fluorotryptophan; FU, 5-fluorouracil;
FN, 5-fluoronucleotides (deoxy and non-deoxy) and FUDP-
sugars, FBAL, a-fluoro-fl-alanine.
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Figure 6 Metabolism by Walker carcinosarcoma of 5FU
(120mgkg-1) in the presence of HPP. Rats received an i.v. bolus
injection of 5FU at zero time, 15min after a molar equivalent
i.v. bolus injection of HPP. The spectral parameters and the
processing of results were identical to that described in the
legend to Figure 4.
and Figure 8 demonstrate that the areas of the signals (peak
integrals) measured by MRS in vivo were proportional to the
final concentrations measured in the extracts. Thus, increases
in the dose of 5FU produced an increase in the FNuct peak
integral which reflected significant increases in the FNuct
concentrations in the tumour. Similarly, HPP caused a large
Figure 8 Peak integrals in vivo, vs. concentrations of 5FU and
FNuct measured in extracts from the Walker carcinosarcoma.
Data were used from both the in vivo (peak integral) and in vitro
(quantified concentration) values that applied to each individual
tumour. Results are from tumours that received both 50 and
120mgkg-1 5FU doses in the presence (tests) and absence
(controls) of HPP. A, 5FU (controls); V, 5FU (tests); 0,
FNuct. Slopes were generated using linear correlation, r
(5FU)J=0.96; r (FNuct)=0.89.
decrease in the average peak integral of FNuct, i.e. an 86%
and 63% reduction in FNuct concentrations following
50mgkg-1 and 120mgkg-1 5FU doses, respectively. In vivo,
the alteration of 5FU netabolism caused by HPP, which
affected both the FNuct and 5FU peaks, was most evident
as a highly significant decrease in the FNuct/5FU ratio at
both of the 5FU doses (Table II).
The FNuct/5FU ratio in vitro was always greater than that
measured using peak integrals in vivo (Table II), probably
because the measurements were effectively taken at different
times. The peak integral in vivo was determined from a mean
time of 50min and the extracts were made at 67min,
immediately after the MRS accumulation was complete.
Figures 2 and 3 show that the FNuct levels at both 5FU
doses were still increasing at 50min and the 5FU levels were
decreasing. The effect of using these two different time
points would also explain why the two slopes in Figure 8 are
significantly different (P<0.1%): a peak area of 2,000
represents 100nmolg-1 for 5FU, but 240nmolg-1 for
FNuct. Thus the 5FU measurement in vivo (area measured
at 33-67min) would be overestimated and the FNuct
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Table II Comparison of measurements made by MRS in vivo and in vitro of the levels of 5FU and FNuct in
the Walker carcinosarcoma following treatment with 5FU with or without HPP pretreatment
NMR quantitation (in vitro) Peak integrals (in vivo)
FNuct FNuct/FU 5FU FNuct FNuct/FU
Treatment 5FU (nmolg 1) FBal ratio (arbitrary units) ratio (n)
SFU
(25mgkg1) 0 63+21c 23+ 15 - 278+ 194 296+250c 1.0+0.9 (4)
5FU
(50mgkg-1) 24+24 172+35 22+ 12 7.2 746+ 431 1,478+191 1.8+0.4 (3)
5FU+HPP
(50mgkg1) 74+28 24+24a 39+30 0.3+0.3 1,589+ 706 34+ 34a 0.1 +O.lb (4)
5FU
(120mgkg-1) 202+32 273+28 78+ 19 1.4+0.2 3,945+ 595 2,328+576 0.6+0.1 (5)
5FU+HPP
(120mgkg-1) 494+26 101+39b 25+ 4 0.2+0.1 8,112+1,321 645+450 0.1 +0.1 (4)
Samples are the same as in Figures 2 and 3. Results are mean+ s.e. where (n) is the number of tumours. The
times of the spectra were as follows: in vivo, 50min (33-67min); in vitro, 67min.
ap<0.02; bp<0.01, comparing test (5FU+HPP) with control (5FU alone); CP<0.05 comparing the low
dose of 5FU with the 50mgkg-1 5FU dose. All comparisons were made using Student's t test.
measurement in vivo would be underestimated. This artifact,
caused by using such a long accumulation time for the
MRS data, would cause the regression lines to diverge.
Nevertheless, the data in Figure 8 demonstrate that these
peak integral values in all tumours for both 5FU and FNuct
are directly correlated to the tumour concentrations
measured in extracts by MRS in vitro (r =0.96, 5FU;
r=0.89, FNuct) and thus increases in peak integrals in the
Walker carcinosarcoma reflected increasing intracellular
concentrations of 5FU and metabolites. With the shorter
accumulation times available at higher fields similar graphs
would act as calibration curves.
Composition of the FNuct peak
The hplc-determined FNuct peak presented in Table III
consists of the sum of measurements of the tissue
concentrations for FUMP, FUDP, and FUTP. The FNuct
peak, which has a chemical shift of 4.5-5 p.p.m. in vivo
(Keniry et al., 1986), may also have contained contributions
from FdUMP and FUDP-glucose, but these could not be
measured by the method of Prior (1989); this would explain
the systematic difference between the hplc-determined FNuct
peak and the MRS-determined FNuct peak shown in Table
II. Table III demonstrates that FUTP accounts for about
50% of the FNuct signal, which is in good agreement with
measurements made in L1210 cells and HCT-8 cells
(Cadman et al., 1981; Benz & Cadman, 1981). The
proportion is lowered to 13% in tumours from rats receiving
HPP 15min before 5FU.
These data show that lowering the 5FU dose resulted in
significantly lower intracellular concentrations of FUTP, but
that the drug combination with HPP caused a much larger
reduction in FUTP of 94% and 91% for 50 and 120mgkg-1
respectively. There were fairly small differences, however, in
the levels of FUMP following treatment with 5FU and HPP
compared with 5FU alone (Table III). This is surprising
since the locus of HPP action is indirect inhibition of
formation of FUMP from 5FU leading to reduced
concentrations for FUDP and FUTP (Schwartz &
Handschumacher, 1979). It suggests that the conversion of
FUMP to FUDP by nucleoside monophosphate kinase has
become rate-limiting, perhaps because of competition from
other monophosphates, such as orotidine monophosphate,
that are increased following HPP metabolism.
Discussion
5FU is activated by intracellular enzymes to 5-fluoro-
nucleotides (FNuct), two of which (FUTP and FdUMP) are
cytotoxic (Heidelberger et al., 1983). In principle MRS could
be used to observe FNuct formation non-invasively and thus
could be a potential indicator of tumour responsiveness. In
practice, however, FdUMP or the ternary complex of
FdUMP, thymidylate synthase and the co-factor
5,10,methylenetetrahydrofolate are formed at cytotoxic
concentrations that are below the sensitivity of MRS. The
ternary complex has been reported to be NMR-visible in
Table III Effect of SFU alone or in combination with HPP on levels of FUTP and FNuct
in the Walker carcinosarcoma
Hplc quantitation
FUDP FUTP % of NMR-
Treatment FUMP (nmolg-1) FUTP FNuct determined FNuct (n)
SFU
(25mgkg-1) 0 7+ 4 33+12c 41+13d 54 (4)
SFU
(SOmgkg1) 18+ 3 41+12 91+11 150+ 4 53 (3)
SFU+HPP
(50mgkg1) 16+ 9 1+ 1 3+ 3 19+11b 13 (4)
SFU
(120mgkg-1) 67+23 67+14 134+27 267+32 49 (5)
5FU+HPP
(120mgkg-1) 43+23 24+ 8 12+ 8a 78+ 14b 12 (4)
Samples are the same as in Table II, i.e. values are determined from tumours freeze-clamped
67min after treatment with SFU. Results are mean+s.e. where n is the number of tumours.
ap<0.02; bp<0.01 when comparing test (SFU+HPP) with control (5FU alone); cP<0.05; dp<0.01 when comparing the low dose of SFU with the 50mgkg-1 SFU dose. All
comparisons were made using Student's t test.
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human pancreatic adenocarcinoma cells but this result was
not reproducible and required high doses of 5-fluoro-2'-
deoxyuridine in vitro (Malet-Martino et al., 1986).
Intracellularly, FdUMP can reach concentrations up to
5nmolg-1, which would be sufficient to inhibit thymidylate
synthase completely (Berne et al., 1987; Washtein, 1984;
Klubes et al., 1978), but which is still below MR sensitivity
in vivo. In any case, the levels of free intracellular FdUMP
may not correlate with cytotoxicity. For example, the
Walker carcinosarcoma formed 0.4nmolg-1 FdUMP, four
times the concentration synthesised by the 5FU sensitive
L1210 cells, but remained relatively insensitive to a single
dose of 5FU since it cleared FdUMP very rapidly (Klubes et
al., 1978). Similarly, HPP caused a 60% reduction of
FdUMP levels in rat colon carcinoma, but did not affect the
amount of thymidylate synthase inhibition (Berne et al.,
1987). Also, despite thymidylate synthase inhibition, DNA
synthesis can continue through salvage of extracellular
thymidine (Heidelberger et al., 1983).
The mechanism of 5FU cytotoxicity via FUTP remains
less clear. FUTP becomes incorporated into RNA,
interfering with RNA methylation, tRNA formation and
protein synthesis (Heidelberger et al., 1983). Additionally, F-
RNA may persist in vivo and lead to a slow release of 5FU
over many hours (Spears et al., 1984). Increases in the
intracellular concentration of FUTP are associated with
increased cell killing in a number of cell lines (Schwartz &
Handschumacher, 1979; Cadman et al., 1981; Benz &
Cadman, 1981), and FUTP may reach concentrations up to
50 times those of FdUMP (Cadman et al., 1981). These
observations suggest not only that FUTP alone would be
MRS-visible, but also that changes in its concentration in
tumours could be used to predict cytotoxicity.
We have shown using MRS in vivo that FNuct was rapidly
formed in the Walker carcinosarcoma following a single
5FU dose at and above 50mgkg- 1. Analysis of the extracts
from these tumours by MRS in vitro and by hplc
demonstrated that lowering the 5FU dose to 25mgkg-1, or
using combination chemotherapy with HPP, decreased the
intracellular concentration of FNuct. Hplc showed that 50%
of this FNuct in controls was the cytotoxic species FUTP.
Compared to the 50mgkg 1 dose of 5FU, the low dose of
5FU produced 64% less intracellular FUTP, while co-
administration of HPP caused a 90% reduction in FUTP
levels. These large changes in FNuct which can be measured
quantitatively in vitro at a single time-point (in this case
67min) could also be detected in vivo, as a highly significant
change in the FNuct/5FU peak integral ratio. Furthermore,
under the conditions used in these experiments, the levels of
FNuct and 5FU formed in vivo could be estimated since the
peak integrals were shown to be proportional to the final
concentrations measured in the extracts at 67min. Drug
regimes that produced a mean FNuct peak integral below
300 arbitrary units (from Figure 8 this would be
<35 nmol g-1) were associated with reduced cytotoxicity
since they did not cause significant inhibition of tumour
growth. Included in these drug regimes was the 5FU
(50mgkg-1)+HPP combination which produced less FUTP
than the 5FU (25mgkg-1) alone (Table III), even though
the former regime seemed more cytotoxic (Table I). Since the
locus of HPP action is to inhibit the formation of FUMP
this might encourage increased metabolism of 5FU towards
FdUMP if the levels of deoxyribose-l-phosphate are
sufficiently high (Figure 1), leading to a higher proportion of
DNA-directed cytotoxicity in the presence of HPP. However,
as discussed above, this mode of cytotoxicity may not be
significant in the Walker carcinosarcoma (Klubes et al.,
1978), and it could be that at these lower concentrations
FUTP is rapidly incorporated into RNA where it is
undetectable by our methods.
Using MRS in vivo, different levels of FNuct formation
have been reported in murine tumours that have differential
sensitivity to 5FU (Hull et al., 1986). In this case FNuct
formation was observed in the '5FU-resistant' M5076 cells
but was absent in the '5FU-sensitive' sarcoma 180 cells.
However, in this experiment the S180 tumours were highly
necrotic and the M5076 cells were mostly viable and later
results with viable tumours suggested a higher anabolite/
catabolite ratio for S180 compared to M5076 (W. Hull,
personal communication).
5FU was immediately and clearly visible in tumours at
both of the high doses of 5FU. This signal declined at a
faster rate than the FNuct signal increased probably because
5FU underwent catabolism and efflux from the Jissue as well
as anabolism. However, in the presence of HPP the
disappearance of 5FU from tumours was slower. HPP may
reduce hepatic clearance of 5FU in patients (Howell et al.,
1981) and these results suggest an additional effect on
tumour catabolism. Signals corresponding to FNucs were
never observed by MRS in vivo or in vitro (detection limit in
vitro was 10nmolg-1) and could not be distinguished from
other nucleotides on our ion-exchange hplc. Of the possible
catabolic products from 5FU metabolism only FBal was
seen in vivo, but not consistently. Analysis of extracts
showed that in fact FBal was present at all doses of 5FU at
concentrations ranging from a mean of 20 up to
80nmolg-1, suggesting that MRS resolution in vivo was
limited by the broadness of the signal and/or the effect of
saturation due to a long T1 for FBal in vivo. Yet in the
extracts there was no correlation between FBal
concentrations and the concentrations of FNuct or 5FU. It
is possible the FBal we observe owes its source to the rapid
5FU catabolism that occurs in rat liver (Cabanac et al.,
1988) and it may be extracellular. So, neither FBal peaks in
vivo, nor FBal concentrations in vitro, are related to 5FU
cytotoxicity. These observations are similar to that made by
Hull et al. (1988), who did not find a correlation between
clinical success and the pharmacokinetics of 5FU catabolism
in patients receiving 5FU or 5FU plus methotrexate chemo-
therapy.
The use of peak integrals to estimate the concentration of
drugs in vivo may only be appropriate in our experimental
protocol and probably could not universally be applied. It
does suggest, however, that at higher fields and with the
development of quantitative methods, MRS could be used as
a predictive tool by the clinician. It is also pertinent to note
that we have not determined whether multiple treatments of
the same animal would result in the 5FU metabolic profiles
we have described here. Nevertheless, our study of the MRS
signals observed in the Walker carcinosarcoma following an
injection of 5FU or HPP and 5FU, shows that only the
FNuct peak integral predicted which drug regime was likely
to induce tumour regression. To our knowledge this is the
first demonstration that the size of the FNuct peak is
relevant to determining the cytotoxicity of 5FU towards
tumours. Our results suggest that MRS in vivo could assess
the sensitivity of tumours that are responsive to 5FU via the
cytotoxic species FUTP. Furthermore, it has been shown
that the mechanism of action of 5FU can be directed
towards FUTP and RNA cytotoxicity by using methotrexate
(Benz & Cadman, 1981) or thymidine (Takimato et al.,
1987). It is therefore possible that MRS could be used to
determine the optimal scheduling of this type of combination
chemotherapy. These possibilities are currently under
investigation.
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